Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) Director Wladimir Hogenhuis purchased 4,259 shares of the stock in a transaction dated Tuesday, September 24th. The shares were purchased at an average cost of $4.70 per share, for a total transaction of $20,017.30. Following the transaction, the director now owns 41,767 shares in the company, valued at approximately $196,304.90. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Rezolute Price Performance
NASDAQ RZLT opened at $4.69 on Wednesday. The stock has a market capitalization of $188.23 million, a P/E ratio of -4.11 and a beta of 1.18. The firm’s 50-day moving average is $4.62 and its two-hundred day moving average is $3.78. Rezolute, Inc. has a 12 month low of $0.72 and a 12 month high of $6.10.
Rezolute (NASDAQ:RZLT – Get Free Report) last issued its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). As a group, analysts anticipate that Rezolute, Inc. will post -1.15 EPS for the current year.
Institutional Trading of Rezolute
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the stock. Guggenheim assumed coverage on shares of Rezolute in a research report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Rezolute in a research report on Monday, September 9th. Craig Hallum started coverage on shares of Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price on the stock. Maxim Group upped their target price on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Tuesday, August 6th. Finally, BTIG Research upped their target price on shares of Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $11.57.
Get Our Latest Analysis on Rezolute
About Rezolute
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Stories
- Five stocks we like better than Rezolute
- What Investors Need to Know to Beat the Market
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What Investors Need to Know About Upcoming IPOs
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.